Luis Marcos
Overview
Explore the profile of Luis Marcos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cherala R, Marcos L, Frageau J
J Brown Hosp Med
. 2025 Mar;
3(3):117603.
PMID: 40026399
Lyme disease is a tick-borne illness caused by the spirochete Borrelia burgdorferi. We present a unique case of a patient who developed acute pancreatitis secondary to infection with B. burgdorferi....
2.
Luther V, Barsoumian A, Konold V, Vijayan T, Balba G, Benson C, et al.
Open Forum Infect Dis
. 2023 Jul;
10(6):ofad289.
PMID: 37397270
The Infectious Diseases Society of America (IDSA) has set clear priorities in recent years to promote inclusion, diversity, access, and equity (IDA&E) in infectious disease (ID) clinical practice, medical education,...
3.
Marcos L, Maco V, Terashima A
Expert Rev Anti Infect Ther
. 2020 Dec;
19(7):817-823.
PMID: 33267701
Introduction: The only drug effective against the infection caused by or is triclabendazole (TCBZ), recommended by the WHO and recently approved by the FDA. Here, we describe the evolution of...
4.
Machicado C, Bertani S, Herrera-Velit P, Espinoza J, Ruiz E, Marcos L
Rev Soc Bras Med Trop
. 2018 May;
51(2):231-233.
PMID: 29768560
Introduction: The etiology of several hepatocellular carcinoma (HCC) cases remains largely unknown. Although Fasciola hepatica has been associated with liver fibrosis in Latin America, it has not yet been associated...
5.
Maco V, Marcos L, Delgado J, Herrera J, Nestares J, Terashima A, et al.
Rev Soc Bras Med Trop
. 2015 Aug;
48(4):445-53.
PMID: 26312936
Introduction: The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica , involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are...
6.
Terashima A, Marcos L, Maco V, Canales M, Samalvides F, Tello R
Rev Gastroenterol Peru
. 2010 Jan;
29(4):305-10.
PMID: 20066014
Objective: The objective of this study was to evaluate the diagnostic efficacy of the Spontaneous Sedimentation in Tube Technique (SSTT) described by Tello, in comparison with the direct smear and...
7.
Espinoza J, Maco V, Marcos L, Saez S, Neyra V, Terashima A, et al.
Am J Trop Med Hyg
. 2007 May;
76(5):977-82.
PMID: 17488926
The performance of Fas2-ELISA for the diagnosis of Fasciola hepatica infection in children living in areas of high endemicity for fascioliasis in the Peruvian Andes is analyzed. Fas2-ELISA is based...
8.
Marcos L, Romani L, Florencio L, Terashima A, Canales M, Nestares J, et al.
Rev Gastroenterol Peru
. 2007 Apr;
27(1):31-6.
PMID: 17431434
Introduction: The infection caused by F. hepatica is endemic in Perú with an increasing number of endemic areas, the reporting of them is essential to know the impact of the...
9.
De Almeida M, Ferreira M, Planchart S, Terashima A, Maco V, Marcos L, et al.
Rev Inst Med Trop Sao Paulo
. 2007 Mar;
49(1):31-5.
PMID: 17384817
Fascioliasis is an emerging/re-emerging vector-borne disease with the widest known distribution. Approximately 17 million people are infected around the world, being the Andean region the most affected area. There is...
10.
Herrera J, Marcos L, Terashima A, Alvarez H, Samalvides F, Gotuzzo E
Rev Gastroenterol Peru
. 2007 Jan;
26(4):357-62.
PMID: 17211485
In order to determine the epidemiological factors and clinical symptoms associated with Strongyloides stercoralis infection, we carried out a descriptive study with a control group in the District of Chanchamayo,...